Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into unsecured and interest free convertible loan agreements with two investors for an aggregate principal loan amount of US$291,545.
Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.
Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, announced that its enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method has been undergoing clinical trial in China, for eventual application to the National Medical Product Administration.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) announced that it has received notification that its latest enhanced COVID-19 Antigen Rapid Test Kit has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended.